|
|
Article: Inspire Pharmaceuticals Announces Initiation of Phase III Trial in Perennial Allergic Rhinitis.
- Article from:
- PR Newswire
- Article date:
- November 21, 2002
CopyrightCOPYRIGHT 2002 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Inspire Pharmaceuticals, Inc. today announced the initiation of a Phase III clinical trial of INS37217 Intranasal in patients with perennial allergic rhinitis (PAR). The trial is a randomized, parallel-group, double-blind study designed to evaluate the safety and efficacy of INS37217 Intranasal in a 10mg/ml non-preserved nasal spray formulation, compared to placebo. This dose was selected based on efficacy results from Phase I and II studies of INS37217 Intranasal in which the 10mg/ml dose consistently demonstrated the most robust effect. The 28-day Phase III study will be conducted in approximately 630 patients at 24 centers across the United States. The primary ...